Archives

  • 2018-07
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • 2022-02
  • 2022-03
  • 2022-04
  • 2022-05
  • 2022-06
  • 2022-07
  • 2022-08
  • 2022-09
  • 2022-10
  • 2022-11
  • 2022-12
  • 2023-01
  • 2023-02
  • 2023-03
  • 2023-04
  • 2023-05
  • 2023-06
  • 2023-08
  • 2023-09
  • 2023-10
  • 2023-11
  • 2023-12
  • 2024-01
  • 2024-02
  • 2024-03
  • 2024-04
  • In the second part of this study we investigated

    2022-05-19

    In the second part of this study, we investigated the influence of GH on the tgf beta receptor 1 of the ghrelin receptor, GHSR-1a, at the mRNA and peptide levels in cultured whole follicles. Regulation of the expression of GHSR-1a has a key role in the actions of ghrelin in target tissues. Using RT-PCR and Western blots, we demonstrated no effect of exogenous GH on either GHSR-1a protein levels or mRNA expression in the ovary (Fig. 1). The results of presented here are not in agreement with Nass et al. [21], who showed that expression of GHSR-1a mRNA was inhibited by GH in rat pituitary tumor tissue. However, it was questionable if this effect was related to direct GH effects on the pituitary or tgf beta receptor 1 the hypothalamus or the result of an altered concentration of the natural ligand for this receptor. Inhibition of GHSR-1a mRNA expression in rat pituitary tissue by insulin growth factor (IGF) was noted by Kamegai et al. [22]. There is also data showing regulation of GHSR-1a expression by glucocorticoids [23], thyroid hormone [24] and sex steroids [25]. Another interesting finding of this study was evidence for the ability is ghrelin through the receptor GHS-R1a can modulate ovarian functions, including estradiol secretion, aromatase activity, caspase-3 activity and cell proliferation. Previously, we showed the stimulatory action of GH but not IGF-I on ghrelin synthesis and secretion by ovarian cells, suggesting the possibility of a feedback loop of GH and ghrelin but not of IGF-I and ghrelin in the ovary [12]. In order to study receptor dependent mechanism of ghrelin action in ovarian function, we used a ghrelin receptor antagonist, (d-Lys-3)-GHRP-6, in cultured ovarian cells. For many years, (d-Lys-3)-GHRP-6 has been reported as a synthetic selective antagonist of the ghrelin receptor, GHSR-1a, and its functional properties have been extensively studied both in vitro and in vivo in animals [26], [27], [28]. In cultures treated together ghrelin and (d-Lys-3)-GHRP-6, estradiol secretion, aromatase activity and cell proliferation returned to control levels (Fig. 2A, B, D), suggesting GHSR-1a receptor mediated action. On the other hand, the inhibitory action of ghrelin on caspase-3 activity seems to be independent of the ghrelin receptor, GHSR-1a, because inhibition of caspase-3 activity was not reversed by a selective antagonist of GHSR-1a (Fig. 2C). Our data are in accordance with the data of Sirotkin et al. [19], which showed that ghrelin was able to modulate the expression of several markers of apoptosis, including bax, bcl-2, caspase-3 activity and p53, while GHSR-1a expression was unnecessary. Baldanzi et al. [29] reported that cardiomyocytes ghrelin and its acylated form, des-acyl ghrelin exhibits an anti-apoptotic effect through binding to a novel, unidentified receptor that is distinct from GHSR-1a. They suggest that ghrelin anti-apoptotic activity is not mediated by GHSR-1a because no expression of GHSR-1a was detected in cardiomyocytes. Moreover, both ghrelin and des-acyl ghrelin, recognize a common high similar binding site, although only ghrelin and not des-acyl ghrelin bind to GHSR-1a receptor [1]. The putative novel receptor is expected to be highly similar to GHSR-1a, since it differs only lack of ability to distinguish between un- and estrified ghrelin peptide. Whether such receptor is encoded by alternative splicing of GHSR-1a gene or by a distinct gene still remains to be determined [29]. Granata et al. [30] showed that ghrelin receptor expression in HIT-T15 pancreatic β-cell line was no found and they suggest that ghrelin proliferative and anti-apoptotic action in these cells was mediated by a distinct and yet unidentified receptor. Similarly, Delhanty et al. [31] reported that anti-apoptotic pathway in adrenocortical tumor cells is not mediated by GHSR-1a in these cells. However, there are one data of Chung et al. [32] reported neuroprotective effect of ghrelin appears to be mediated through the activation of GHSR-1a because (d-Lys-3)-GHRP-6 completely blocks the protective effect of ghrelin against oxygen–glucose deprivation insult. We suggest that independent of GHSR-1a anti-apoptotic action of ghrelin could be due to its binding to a novel unknown receptor in the pig ovary. For example in chicken ovarian tissue three splice variants of GHSR-1a were expressed [19]. Results of our unpublished data showed that anti-apoptotic effect of ghrelin on caspase-3 activity and DNA fragmentation is mediated by intracellular signaling pathway MAPK and phosphatidylinositol (PI) 3-kinase.